DocMorris, the Swiss online pharmacy, raised its full-year revenue growth forecast to between 9% and 13% after reporting a 12.5% increase in first-half sales to 627.8 million francs.
The company attributed the strong performance primarily to a surge in prescription drug sales, which rose 38.3% year-on-year, while its Digital Services segment grew by approximately 71%. Chief Executive Walter Hess noted that revenue momentum and operational efficiency had improved across all business areas in the first half of 2026.
Finance Chief Daniel Wüest confirmed the target to reach break-even profitability in the second half of the year. The adjusted EBITDA loss narrowed to 10.9 million francs, more than halving from the prior period’s 23.8 million francs.
For the full year, DocMorris now expects adjusted EBITDA to range between a loss of 10 million and 17.5 million francs, compared with its previous guidance. The company did not provide specific details on profitability expectations beyond the second-half break-even target.
The online pharmacy, led by Hess since April 2022, has seen growing adoption of e-prescriptions, which has driven demand for prescription medications through its platform.
